Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Blight

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Clinical Therapeutics|January 30, 2017
Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot StudyFrancois Bethoux, Ali Fatemi, Eileen Fowler, et al.
Neurology|August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman, T R Brown, J A Cohen, et al.
Spinal Cord|November 13, 2013
Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injuryD D Cardenas, J F Ditunno, V Graziani, et al.
Topics in Spinal Cord Injury Rehabilitation|December 15, 2012
Outcome Measures for Acute/Subacute Cervical Sensorimotor Complete (AIS-A) Spinal Cord Injury During a Phase 2 Clinical TrialJohn D Steeves, Daniel P Lammertse, John L K Kramer, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 3, 2007
Increased cerebral and renal endothelial nitric oxide synthase gene expression after cardiopulmonary bypass in the ratC David Mazer, Francoise Briet, Katherine R Blight, et al.
Clinical Neuropharmacology|August 5, 2003
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryKeith C Hayes, Patrick J Potter, Robert R Hansebout, et al.
Critical Care Medicine|April 13, 1999
Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injuryM J Bell, P M Kochanek, M P Heyes, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 17, 1998
Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humansE H Sinz, P M Kochanek, M P Heyes, et al.
Stroke|May 9, 2013
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusionJennifer F Iaci, Tom J Parry, Zhihong Huang, et al.
International Journal of MS Care|June 9, 2015
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled TrialRobert Yapundich, Angela Applebee, Francois Bethoux, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Clinical Therapeutics|January 30, 2017
Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot StudyFrancois Bethoux, Ali Fatemi, Eileen Fowler, et al.
Neurology|August 2, 2008
Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman, T R Brown, J A Cohen, et al.
Spinal Cord|November 13, 2013
Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injuryD D Cardenas, J F Ditunno, V Graziani, et al.
Topics in Spinal Cord Injury Rehabilitation|December 15, 2012
Outcome Measures for Acute/Subacute Cervical Sensorimotor Complete (AIS-A) Spinal Cord Injury During a Phase 2 Clinical TrialJohn D Steeves, Daniel P Lammertse, John L K Kramer, et al.
The Journal of Thoracic and Cardiovascular Surgery|January 3, 2007
Increased cerebral and renal endothelial nitric oxide synthase gene expression after cardiopulmonary bypass in the ratC David Mazer, Francoise Briet, Katherine R Blight, et al.
Clinical Neuropharmacology|August 5, 2003
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryKeith C Hayes, Patrick J Potter, Robert R Hansebout, et al.
Critical Care Medicine|April 13, 1999
Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injuryM J Bell, P M Kochanek, M P Heyes, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|June 17, 1998
Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humansE H Sinz, P M Kochanek, M P Heyes, et al.
Stroke|May 9, 2013
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusionJennifer F Iaci, Tom J Parry, Zhihong Huang, et al.
International Journal of MS Care|June 9, 2015
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled TrialRobert Yapundich, Angela Applebee, Francois Bethoux, et al.
Pageof 12